Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence-guided intraoperative margin analysis in oral squamous cell carcinoma
NL-OMON58328Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of cetuximab-IRDye 800CW in Oral Mucosal Carcinoma and head and neck cancer (HNC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Surgical outcome by margin status, Rate of margin conversion and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
Oral Mucosal Carcinomahead and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON58328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58328.